Novel tumor mutation score versus tumor mutation burden in predicting survival after immunotherapy in pan-cancer patients from the MSK-IMPACT cohort

BACKGROUND: Tumor mutation burden (TMB) may predict the immune checkpoint inhibitor (ICI) response. The TMB calculation includes all nonsynonymous somatic mutations, but not all mutations are favorable, and the efficiency of TMB is attenuated by including adverse mutations. Moreover, no universal cu...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yuan, Chen, Zuhua, Wu, Long, Tao, Weiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210182/
https://www.ncbi.nlm.nih.gov/pubmed/32395490
http://dx.doi.org/10.21037/atm.2020.03.163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210182/
https://www.ncbi.nlm.nih.gov/pubmed/32395490
http://dx.doi.org/10.21037/atm.2020.03.163

Ejemplares similares